Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB‐IIIC vs stage IV epithelial ovarian cancer after primary surgery
Open Access
- 31 August 2018
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (1) , 34-43
Abstract
Introduction: The objective of this study was to determine the impact of intra‐abdominal residual disease size, type (carcinomatosis, tumor mass or both), and location (upper/lower abdominal/both) on overall survival in women with Federation of Gynecology and Obstetrics (FIGO) stage IIIB‐IIIC vs stage IV epithelial ovarian cancer who underwent primary debulking surgery.Material and methods: Altogether 2092 women diagnosed with advanced epithelial ovarian cancer undergoing primary debulking surgery in Denmark during 2005‐2016 were identified in the Danish Gynecological Cancer Database. The impact of residual disease size, type, and location were evaluated using univariate and multivariate analyses.Results: Complete cytoreduction (residual disease = 0) was achieved in 47.3% and 38.4% of women with stage IIIB‐IIIC and IV epithelial ovarian cancer, respectively. A benefit in overall survival was observed in women with residual disease = 0 compared with women with residual disease, and among women with residual disease ≤1 cm compared with residual disease >2 cm in both stages IIIB‐IIIC and stage IV in multivariate analyses. Multivariate analyses showed an inferior overall survival for women with both residual carcinomatosis and residual tumor mass compared with those with residual tumor mass or residual carcinomatosis only for stage IIIB‐IIIC and IV, and an inferior overall survival for women with residual disease located in both the upper and lower abdomen compared with residual disease in the upper abdomen only in stages IIIB‐IIIC.Conclusions: Our results confirm the positive prognostic impact of both complete cytoreduction and residual disease ≤1 cm in stages IIIB‐IIIC as well as stage IV epithelial ovarian cancer. Women with stage IV do benefit from cytoreductive surgery and should be considered for primary debulking surgery, if residual disease = 0 can initially be expected.Keywords
This publication has 30 references indexed in Scilit:
- Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IVInternational Journal of Gynecological Cancer, 2012
- Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish surveyActa Obstetricia et Gynecologica Scandinavica, 2010
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian CancerNew England Journal of Medicine, 2010
- Influence of Residual Tumor on Outcome in Ovarian Cancer Patients With FIGO Stage IV DiseaseAnnals of Surgical Oncology, 2010
- Residual Cancer Stem Cells after Interval Cytoreductive Surgery following Neoadjuvant Chemotherapy Could Result in Poor Treatment Outcomes for Ovarian CancerOnkologie, 2010
- Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2008
- Prognostic Factors of Stage IV Epithelial Ovarian Cancer: A Multicenter Retrospective StudyGynecologic Oncology, 2001
- Stage IV Ovarian Cancer: Impact of Surgical Debulking1Gynecologic Oncology, 1997
- Prognostic Significance of Residual Disease in Patients with Stage IV Epithelial Ovarian CancerGynecologic Oncology, 1997
- The Prognostic Significance of Residual Disease, FIGO Substage, Tumor Histology, and Grade in Patients with FIGO Stage III Ovarian CancerGynecologic Oncology, 1995